Perinatal Outcome After Intrauterine Transfusion in Rh Isoimmunized Mothers

  • Omkar Potdar
  • Hemraj R. Narkhede
  • Purnima R. Satoskar
Original Article



The objective of the study was to assess the fetal outcome after receiving intrauterine transfusion (IUT) in Rh-isoimmunized pregnancy in a tertiary care center.

Study Design

This was a retrospective observational descriptive study in which all Rh-negative gravidas with isoimmunization warranting IUTs (40 patients) were analyzed during the period from January 1, 2010 to October 31, 2015. Primary outcome variables were fetal outcomes and procedural-related factors.


Forty pregnancies (13—hydropic, 27—non-hydropic) required 74 IUTs. IUT was performed at gestational age of 15.4–33 weeks when indicated. The amount of blood transfused ranged from 4 to 110 ml. There were two sudden intrauterine fetal deaths during the procedure, four post-procedure intrauterine fetal deaths in fetuses with severe hydrops, and three neonatal deaths. The overall survival rate was found to be 77.5%.


IUT was found to be an effective therapy in correcting anemia in fetuses of Rh isoimmunized mothers. Early diagnosis of fetal anemia and intrauterine blood transfusion by an experienced fetal medicine specialist is very important for the perinatal outcome.


Rh isoimmunization Fetal anemia Intrauterine blood transfusion Fetal outcome 


Authors’ Contributions

PRS designed the study model, performed IUT, and reviewed the article; HRN assisted in the IUT, wrote the article, and helped in compilation and analysis of data; and OP assisted in the IUT, compiled and analyzed the data, and helped in article write-up.

Compliance with Ethical Standards

Conflict of interest

The authors have no conflicts of interest.

Ethical Approval

For this type of study, formal consent is not required and waiver consent was obtained.

Human and Animal Rights

Retrospective observation study analyzes records of Rh-sensitized women in pregnancy.

Informed Consent

Waiver consent was taken.


  1. 1.
    Bowman JM. Haemolytic disease of the fetus (Erythroblastsis fetalis). In: Creasy RK, Rensnik R, editors. Maternal-fetal medicine. 7th ed. Philadelphia: W.B. Saunders; 2014. p. 558–68.Google Scholar
  2. 2.
    Badran EF, Al-lawama M, Masri A, et al. Fetal intrauterine transfusion therapy: neonatal outcomes. J Blood Lymph. 2013;3:112.Google Scholar
  3. 3.
    Zwiers C, Lindenburg ITM, Klumper FJ, et al. Complications of intrauterine intravascular blood transfusion: lessons learned after 1678 procedures. Ultrasound Obstet Gynecol. 2017;50(2):180–6.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Moise KJ Jr. Management of rhesus alloimmunization in pregnancy. Obstet Gynecol. 2008;112(1):164–76.CrossRefPubMedGoogle Scholar
  5. 5.
    Tiblad E, Kublickas M, Ajne G, et al. Procedure-related complications and perinatal outcome after intrauterine transfusions in red cell alloimmunization in Stockholm. Fetal Diagn Ther. 2011;30(4):266–73.CrossRefPubMedGoogle Scholar
  6. 6.
    Urbaniak SJ, Greiss MA. RhD haemolytic disease of the fetus and the newborn. Blood Rev. 2000;14(1):44–61.CrossRefPubMedGoogle Scholar
  7. 7.
    Alec Mc Ewan. Red cell alloimmunization. In: Pavord S, Hunt B, editors. The obstetric hematology manual. New York: Cambridge University Press; 2010. p. 73–88.Google Scholar
  8. 8.
    Wong KS, Connan K, Rowlands S, et al. Antenatal immunoglobulin for fetal red blood cell alloimmunization. Cochrane Database Syst Rev. 2013;5:CD008267.Google Scholar
  9. 9.
    Mari G, Adrignolo A, Abuhamad AZ, et al. Diagnosis of fetal anemia with Doppler ultrasound in the pregnancy complicated by maternal blood group immunization. Ultrasound Obstet Gynecol. 1995;5(6):400–5.CrossRefPubMedGoogle Scholar
  10. 10.
    Pasman SA, Claes L, Lewi L, et al. Intrauterine transfusion for fetal anemia due to red blood cell alloimmunization: 14 years’ experience in Leuven. Facts Views Vis ObGyn. 2015;7(2):129–36.PubMedPubMedCentralGoogle Scholar
  11. 11.
    Lindenburg IT, Smits-Wintjens VE, van Klink JM, et al. Long-term neurodevelopmental outcome after intrauterine transfusion for hemolytic disease of the fetus/newborn: the LOTUS study. Am J Obstet Gynecol. 2012;206(2):141.CrossRefPubMedGoogle Scholar
  12. 12.
    Vatsla D, Deepika D, Sumana G, et al. Treatment of fetal anemia in Rh isoimmunized pregnancies with intrauterine fetal blood transfusion. J Obstet Gynaecol India. 2010;60(2):135–40.CrossRefPubMedCentralGoogle Scholar
  13. 13.
    Altunyurt S, Okyay E, Saatli B, et al. Neonatal outcome of fetuses receiving intrauterine transfusion for severe hydrops complicated by Rhesus hemolytic disease. Int J Gynecol Obstet. 2012;117:153–6.CrossRefGoogle Scholar
  14. 14.
    Deka D, Dadhwal V, Sharma AK, et al. Perinatal survival and procedure-related complications after intrauterine transfusion for red cell alloimmunization. Arch Gynecol Obstet. 2016;293(5):967–73.CrossRefPubMedGoogle Scholar
  15. 15.
    Bujandric N, Grujic J. Exchange Transfusion for Severe Neonatal Hyperbilirubinemia: 17 years’ experience from Vojvodina, Serbia. Indian J Hematol Blood Transfus. 2016;32(2):208–14.CrossRefPubMedGoogle Scholar

Copyright information

© Federation of Obstetric & Gynecological Societies of India 2018

Authors and Affiliations

  • Omkar Potdar
    • 1
  • Hemraj R. Narkhede
    • 1
    • 2
  • Purnima R. Satoskar
    • 1
  1. 1.Department of Obstetrics and GynecologySeth GS Medical College, Nowrosjee Wadia Maternity HospitalParel, MumbaiIndia
  2. 2.MumbaiIndia

Personalised recommendations